Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis

• Market Cap: ₹135.13B
• Dividend Yield: 0.31%
• Average Volume (3M): 3.75K
• Price to Earnings (P/E): 22.9
• Beta (1Y): 1.39
• Revenue Growth: 11.41%
• EPS Growth: 19.22%
• Country: IN
• Employees: 3,406
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 20.30
• Shares Outstanding: 76,011,696
• 10 Day Avg. Volume: 2,866
• 30 Day Avg. Volume: 3,752
• PEG Ratio: 1.63
• Price to Book (P/B): 5.30
• Price to Sales (P/S): 7.78
• P/FCF Ratio: 62.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: ₹1,947.00 ▲(5.47% Upside)

Caplin Point Laboratories' strong financial performance is the primary driver of its stock score, reflecting robust revenue growth and solid profitability. However, technical indicators suggest a bearish trend, and the valuation appears moderately high, which tempers the overall score.

Positive Factors

Strong revenue and profitability

Sustained revenue growth and robust gross/EBITDA margins indicate efficient cost management and durable operating leverage. Strong profitability across periods supports reinvestment into complex dosage forms, funds R&D/registrations and underpins long-term cash generation.

Solid balance sheet with low leverage

A low leverage profile and high equity ratio provide financial resilience and flexibility for capital spending or acquisitions. Prudent balance sheet positioning reduces refinancing risk and lets management fund regulatory compliance and international market expansion reliably.

Consistent free cash flow generation

Repeated free cash flow growth and strong operating cash conversion support sustainable investment in manufacturing capacity and registrations. Reliable cash generation enables debt reduction and funds launches across multiple markets without diluting shareholders.

Negative Factors

Revenue exposure to tender-driven sales and distributors

Heavy reliance on tenders and third-party distribution creates structural revenue volatility and pricing pressure. Winning volume is cyclical and margins are often pressured in tender markets, which can weaken long-term predictability and margin sustainability.

Regulatory and approval dependence in international markets

Growth depends on obtaining and maintaining product registrations across jurisdictions. Delays, stricter regulations or compliance failures in injectables/ophthalmics can block launches, raise costs and materially defer revenues over multi-quarter timelines.

Exposure to intense generic competition

Operating in generics means sustained pricing pressure and buyer leverage, especially in commoditized segments. Even with differentiated dosage forms, competition and tender price downward pressure can compress margins and limit long-term pricing power.

Caplin Point Laboratories Limited Business Overview & Revenue Model

Company Description

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.

How the Company Makes Money

Caplin Point Laboratories generates revenue through multiple streams, primarily from the sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company has a robust export business, catering to markets across various continents, which significantly contributes to its earnings. Additionally, CAPLIPOINT engages in contract manufacturing for other pharmaceutical companies, providing it with a steady income source. The company also benefits from strategic partnerships and collaborations that enhance its product offerings and market reach. Its revenue model is bolstered by a focus on research and development, allowing it to innovate and expand its product portfolio in response to market demands.

Caplin Point Laboratories Limited Financial Statement Overview

Summary

Caplin Point Laboratories exhibits strong financial health with impressive revenue growth, efficient operations, and solid profitability. The balance sheet is robust with low leverage and high equity, while cash flow generation is ample and sustainable.

Income Statement

Caplin Point Laboratories has demonstrated strong revenue growth, with a significant increase in total revenue over the past five years. The gross profit margin is robust, indicating efficient cost management. Additionally, the EBIT and EBITDA margins highlight strong operational performance, while the net profit margin reflects effective bottom-line management.

Balance Sheet

The company's balance sheet is solid, featuring a low debt-to-equity ratio which suggests prudent financial leverage. The equity ratio is high, showcasing a strong equity position relative to total assets. Return on equity has shown positive trends, reflecting good profitability on shareholders' investments.

Cash Flow

Caplin Point Laboratories has a healthy cash flow, with consistent growth in free cash flow. The operating cash flow to net income ratio indicates strong cash generation relative to net income, supporting business sustainability. The free cash flow to net income ratio is solid, ensuring ample cash availability for reinvestment or debt reduction.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	19.91B	19.40B	16.96B	14.68B	12.71B	10.62B
Gross Profit	11.79B	11.38B	9.40B	7.89B	6.99B	5.82B
EBITDA	6.73B	6.49B	5.51B	4.40B	3.94B	3.28B
Net Income	5.65B	5.36B	4.57B	3.76B	3.00B	2.42B
Balance Sheet
Total Assets	0.00	32.09B	26.98B	21.91B	17.36B	13.64B
Cash, Cash Equivalents and Short-Term Investments	9.03B	9.03B	7.88B	6.50B	5.13B	4.46B
Total Debt	0.00	50.20M	19.70M	54.80M	21.30M	183.92M
Total Liabilities	-28.86B	3.22B	3.51B	2.84B	2.26B	1.60B
Stockholders Equity	28.86B	28.50B	23.16B	18.80B	14.84B	11.86B
Cash Flow
Free Cash Flow	0.00	2.41B	1.73B	779.00M	2.46B	1.95B
Operating Cash Flow	0.00	4.32B	3.18B	2.72B	3.37B	2.66B
Investing Cash Flow	0.00	-3.35B	-3.20B	-2.18B	-3.77B	-294.40M
Financing Cash Flow	0.00	-383.20M	-380.70M	-281.70M	-407.10M	-239.78M

Caplin Point Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1845.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Negative. The current price of 1845.95 is above the 20-day moving average (MA) of 1791.27, below the 50-day MA of 1864.88, and below the 200-day MA of 2010.28, indicating a bearish trend. The MACD of -37.96 indicates Negative momentum. The RSI at 45.64 is Neutral, neither overbought nor oversold. The STOCH value of 51.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAPLIPOINT.

Caplin Point Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹149.64B	9.72	―	0.57%	-3.79%	-20.88%
GRANULES	73 Outperform	₹138.45B	25.38	―	0.24%	8.14%	5.18%
CAPLIPOINT	69 Neutral	₹135.13B	22.95	―	0.31%	11.41%	19.22%
NEULANDLAB	67 Neutral	₹169.90B	70.75	―	0.08%	0.34%	-14.13%
APLLTD	60 Neutral	₹153.63B	24.22	―	1.28%	11.42%	-1.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Caplin Point Laboratories Limited Corporate Events

Caplin Point Buys $473 Million Portfolio of US-Approved Injectable and Ophthalmic ANDAs

Caplin Point Laboratories, through its subsidiaries Caplin Steriles and Caplin One Labs, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic manufacturer, covering an addressable market of $473.2 million for the year ended August 2025. The deal strengthens Caplin’s U.S. portfolio—now including select oncology injectables to be commercialized from its new oncology facility in Kakkalur—and supports its strategy to deepen presence in the U.S. while progressively rolling out these products to key non-U.S. markets such as Mexico, Canada, the European Union and Brazil, reinforcing the company’s positioning as a growing global player in sterile and oncology generics.

Caplin Steriles Secures USFDA Approval for Acetaminophen Injection

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received USFDA approval for its Acetaminophen Injection in single-dose infusion bags. This approval marks a significant milestone for Caplin Steriles, allowing it to offer a generic equivalent of a drug with substantial market sales in the US, potentially enhancing its market position and expanding its product offerings in the US pharmaceutical market.

Caplin Point Laboratories Announces Financial Results and New Appointments

Caplin Point Laboratories Limited announced the approval of its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The company also appointed Mr. Ashok Partheeban and Mr. Vivek Partheeban as Additional Directors and Vice-Chairmen, with Mr. Vivek Partheeban relinquishing his position as Chief Operating Officer. Additionally, Dr. K C John was appointed as a Non-Executive Independent Director for a five-year term.